The Center is dedicated to improving kidney patients’ quality of life and reducing the occurrence of ESRD through education and by developing awareness of dialysis and kidney disease issues, improving the partnership between patients and caregivers, and developing favorable public policy solutions.
We all know that sleep is important, yet many of us never seem to get enough of it. The journal Sleep Review recently found that 67% of end-stage renal disease patients said they were impacted by sleep disorders that prevented them from getting enough sleep. These sleep disorders include periodic leg movement syndrome (PLMS), restless legs syndrome (RLS), insomnia and sleep apnea.
A recent study conducted by the University of Cincinnati found that patient outcomes were almost identical for generic and brand-name versions of tacrolimus, a drug used post-transplant to reduce the risk of organ rejection. With more affordable generics now on the market, the study took a closer look at the outcomes of what have often been referred to as narrow therapeutic index medications.